Therapeutic Areas
RNAlytiX develops technologies designed to uncover hidden biological variability associated with disease progression, treatment response, and clinical outcomes.
Our initial focus spans therapeutic areas where biological heterogeneity remains a major challenge and where improved molecular understanding could transform people’s lives.
Oncology
Understanding therapeutic response and resistance
Cancer remains one of the clearest examples of biological diversity hidden beneath similar clinical presentation.
Patients receiving the same therapy frequently show markedly different responses, while resistance mechanisms often emerge before conventional monitoring can detect them.
RNAlytiX is exploring applications in:
Patient stratification
Identifying biologically distinct subgroups within clinically similar populations.
Therapy response and resistance monitoring
Supporting longitudinal assessment of treatment dynamics.
Clinical development
Enabling biomarker programmes and translational partnerships.
Areas of interest include haematological malignancies, solid tumours, and therapy resistance.
Neurology
Addressing complexity in neurodegenerative disease
Neurological diseases present profound challenges for diagnosis, monitoring, and patient stratification.
Disease processes frequently begin years before clinical presentation, while molecular changes remain difficult to observe non-invasively.
RNAlytiX is investigating opportunities in:
- Early disease detection
- Longitudinal monitoring
- Patient stratification
- Mechanistic insight generation
Initial areas include neurodegenerative disorders and CNS malignancies.
Cardiovascular Medicine
Towards earlier biological detection
Many cardiovascular conditions are detected only after substantial biological change has already occurred.
RNAlytiX is interested in applications where earlier molecular insight could support clinical decision-making and improve outcomes.
Areas of investigation include:
- Transplant medicine
- Monitoring of biological stress and tissue response
- Precision cardiovascular biomarkers
Metabolic Disease
Improving biological resolution in chronic disease
Metabolic disorders remain among the fastest growing global health burdens.
Yet disease progression frequently occurs across broad biological continua that are difficult to resolve using current approaches.
RNAlytiX is exploring applications including:
- Disease stratification
- Progression monitoring
- Biomarker development
Initial focus includes metabolic liver disease and related translational programmes.
Rare and Translational Diseases
Enabling discovery where data are limited
Rare diseases often suffer from limited patient numbers, fragmented datasets, and incomplete biological understanding.
RNAlytiX is interested in applying advanced biological analytics to support:
- Mechanistic discovery
- Biomarker generation
- Patient subgroup identification
- Translational research collaborations
Designed for translation
Our therapeutic programmes are guided by three principles:
Clinical relevance
Focus on unmet clinical needs.
Biological interpretation
Prioritising understanding over correlation.
Translation
Developing insight that can move from discovery into application.